Myelin Oligodendrocyte Glycoprotein Antibody Disease (MOGAD)

Overview

MOGAD, also referred to as MOG antibody-associated disease, is an immune-mediated inflammatory demyelinating disorder of the central nervous system characterized by antibodies directed against myelin oligodendrocyte glycoprotein (MOG), a protein located on the outer surface of myelin in the brain, optic nerves, and spinal cord.

Although MOGAD involves antibodies directed against a self-protein, current evidence supports classification as an immune-mediated rather than a confirmed autoimmune disease. MOGAD was previously considered part of multiple sclerosis or neuromyelitis optica spectrum disorders (NMOSD), but is now recognized as a distinct disease entity with unique clinical, immunologic, and imaging features.

Clinical course varies, with some individuals experiencing a single demyelinating episode and others developing relapsing disease. Diagnosis relies on detecting MOG-IgG antibodies using validated cell-based assays, interpreted alongside clinical presentation and MRI findings.

Common Symptoms

Vision loss or blurred vision; eye pain with movement; limb weakness; sensory disturbances, such as numbness or tingling; difficulty walking; balance problems; bowel or bladder dysfunction; severe headache; nausea or vomiting; altered consciousness; seizures; cognitive or behavioral changes; and fatigue.

Coexisting Diseases and Conditions

Optic neuritis, acute disseminated encephalomyelitis (ADEM), transverse myelitis, brainstem encephalitis, seizures, neuropathic pain, and other inflammatory demyelinating disorders of the central nervous system.

Risk Factors and Prevalence

The underlying cause of MOGAD is not fully understood. The disease is thought to arise from abnormal immune targeting of the MOG protein, potentially triggered by infections or other immune-activating events in susceptible individuals. MOGAD occurs in both pediatric and adult populations and affects individuals of all sexes.

*Update December 17, 2025: Pathogenic Antibodies Identified in Rare Autoimmune Brain Disease*

Recent Research

Sources

Sources
1. Jarius, S., Paul, F., Aktas, O., Asgari, N., Dale, R. C., de Seze, J., Franciotta, D., Fujihara, K., Jacob, A., Kim, H. J., Kleiter, I., Kümpfel, T., Levy, M., Palace, J., Ruprecht, K., Saiz, A., Trebst, C., Weinshenker, B. G., & Wildemann, B. (2018). MOG encephalomyelitis: international recommendations on diagnosis and antibody testing. Journal of neuroinflammation, 15(1), 134. https://doi.org/10.1186/s12974-018-1144-2
2. Ramanathan, S., Mohammad, S., Tantsis, E., Nguyen, T. K., Merheb, V., Fung, V. S. C., White, O. B., Broadley, S., Lechner-Scott, J., Vucic, S., Henderson, A. P. D., Barnett, M. H., Reddel, S. W., Brilot, F., Dale, R. C., & Australasian and New Zealand MOG Study Group (2018). Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination. Journal of neurology, neurosurgery, and psychiatry, 89(2), 127–137. https://doi.org/10.1136/jnnp-2017-316880
3. Reindl, M., & Waters, P. (2019). Myelin oligodendrocyte glycoprotein antibodies in neurological disease. Nature reviews. Neurology, 15(2), 89–102. https://doi.org/10.1038/s41582-018-0112-x
4. Al-Ani, A., Chen, J. J., & Costello, F. (2023). Myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD): current understanding and challenges. Journal of neurology, 270(8), 4132–4150. https://doi.org/10.1007/s00415-023-11737-8
5. Sechi, E., Cacciaguerra, L., Chen, J. J., Mariotto, S., Fadda, G., Dinoto, A., Lopez-Chiriboga, A. S., Pittock, S. J., & Flanagan, E. P. (2022). Myelin Oligodendrocyte Glycoprotein Antibody-Associated Disease (MOGAD): A Review of Clinical and MRI Features, Diagnosis, and Management. Frontiers in neurology, 13, 885218. https://doi.org/10.3389/fneur.2022.885218
6. Shahriari, M., Sotirchos, E. S., Newsome, S. D., & Yousem, D. M. (2021). MOGAD: How It Differs From and Resembles Other Neuroinflammatory Disorders. AJR. American journal of roentgenology, 216(4), 1031–1039. https://doi.org/10.2214/AJR.20.24061
7. Trewin, B. P., Brilot, F., Reddel, S. W., Dale, R. C., & Ramanathan, S. (2025). MOGAD: A comprehensive review of clinicoradiological features, therapy and outcomes in 4699 patients globally. Autoimmunity reviews, 24(1), 103693. https://doi.org/10.1016/j.autrev.2024.103693
8. Ciampi E. (2025). MOGAD: A Shifting Landscape-From Pathogenesis to Personalised Management, Global Perspectives and Latin American Insights. Biomedicines, 13(10), 2344. https://doi.org/10.3390/biomedicines13102344